A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2015
At a glance
- Drugs Vadimezan (Primary) ; Docetaxel
- Indications Urogenital cancer
- Focus Therapeutic Use
- 17 Aug 2015 Status changed from suspended to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 20 Aug 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 03 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.